- Gene editing technology group Horizon Discovery said it had formed a strategic collaboration with Mammoth Biosciences.

The pact would see the two companies develop new tools to provide the next generation of engineered cell lines for the biopharmaceutical industry.

They would collaborate to identify and optimise Horizon's novel proteins for use under license by Horizon.

Horizon would pay an undisclosed consideration and issue warrants to Mammoth for the exclusive rights being licensed.

At 8:21am: [LON:HZD] Horizon Discovery Group Plc share price was +2.2p at 158.2p

Story provided by